Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2025-01-20 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于公司及子公司使用闲置自有资金购买理财产品进展的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Jinling Pharmaceutical Co., Ltd. regarding the company's and its subsidiaries' use of idle funds to purchase wealth management products. It includes specific data on purchase amounts, dates, maturity, and returns, as well as risk disclosures and control measures. The document is not a financial report like an annual or interim report, nor is it a regulatory filing or certification. It is a capital management update related to the company's financing activities and cash management. The length (6185 characters) and detailed financial data about fund usage and investment products support classification as a Capital/Financing Update (CAP).
2025-01-20 Chinese
金陵药业股份有限公司监事会关于公司及子公司使用闲置自有资金进行委托理财及募集资金进行现金管理的审核意见
Audit Report / Information Classification · 90% confidence The document is a supervisory board's audit opinion regarding the company's and its subsidiaries' use of idle funds for entrusted financial management and cash management of raised funds. It references compliance with regulatory guidelines and company articles but does not contain financial statements or detailed financial data. The document length is short (472 characters), and it is essentially an internal audit opinion or supervisory board review rather than a full audit report or annual report. It does not announce voting results, management changes, or other categories. Given the nature and length, it fits best under Audit Report / Information (AR) as it is a standalone audit opinion related to internal controls and fund usage compliance. FY 2024
2025-01-20 Chinese
金陵药业股份有限公司2025年第一次独立董事专门会议的审查意见
Board/Management Information Classification · 95% confidence The document is titled as the '2025 First Independent Directors Special Meeting Review Opinions' of Jinling Pharmaceutical Co., Ltd. It contains the independent directors' review opinions on specific company matters to be submitted to the board meeting, including related party transactions and fund liquidation. The content is a formal opinion or review from independent directors rather than a full report or announcement of financial results. It does not contain financial statements, earnings data, or regulatory certifications. It is not a general regulatory filing or announcement but a specific board/management related document concerning governance and oversight. Therefore, it fits best under 'Board/Management Information (MANG)' which covers announcements of changes or opinions from the board or senior management bodies.
2025-01-20 Chinese
金陵药业股份有限公司关于2025年度日常关联交易预计情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected related party transactions for the fiscal year 2025 by Jinling Pharmaceutical Co., Ltd. It includes details about the nature of the transactions, pricing principles, related parties, and approvals by the board and independent directors. It also references compliance with Shenzhen Stock Exchange listing rules and includes opinions from the sponsor institution. The document is a formal disclosure of anticipated related party transactions and their governance, not a full financial report or audit. It is a regulatory announcement about related party transactions, which fits best under the category of Regulatory Filings (RNS) as it does not contain full financial statements or detailed financial analysis but is a compliance disclosure.
2025-01-20 Chinese
中信证券股份有限公司关于金陵药业股份有限公司及子公司使用闲置自有资金进行委托理财及闲置募集资金进行现金管理核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the use of idle proprietary funds and idle raised funds by Jinling Pharmaceutical Co., Ltd. and its subsidiaries for entrusted wealth management and cash management. It includes specifics about the amount of funds raised, investment projects, investment purposes, risk control measures, and approvals by the board and supervisory committee. The document also contains the sponsor's verification opinion and legal compliance statements. It is not a brief announcement or a simple notification but a comprehensive verification and opinion report related to the company's capital management activities. This fits the category of Capital/Financing Update (CAP), as it deals with updates on company fundraising and capital usage activities, specifically the management of raised funds and idle capital. The document length is 4266 characters, which is substantial but not a full annual or interim report. It is not a regulatory filing or announcement of a report publication. Therefore, the best classification is CAP with high confidence.
2025-01-20 Chinese
金陵药业股份有限公司关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2025 first extraordinary general meeting (临时股东大会) of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures, agenda items, registration methods, and proxy forms. There is no financial data or report content, but rather an announcement and instructions related to the shareholders' meeting. The document length is under 5,000 characters and it primarily serves as a meeting notice and proxy solicitation. Therefore, it fits best into the category of Proxy Solicitation & Information Statement (PSI).
2025-01-20 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.